Richard Bartram

Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer), MBX Biosciences, Inc.

A later filing names a successor. First published here October 28, 2026; built from records as of October 28, 2026.

Richard Bartram signed the annual report of MBX Biosciences, Inc. on Form 10-K as Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer), filed March 12, 2026.¹ A later filing by MBX Biosciences, Inc., made on July 13, 2026, names John Smither as its chief financial officer; the record holds no filing that reports the end of Richard Bartram's tenure.

Seats

The seat in the record

Company	Title as filed	Standing	Filings
MBX Biosciences, Inc. (MBX) Pharmaceutical Preparations	Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)	A later filing names a successor John Smither, filed July 13, 2026 (filing)	1

Company names link to the company's page in the record at CFO Tribune, which holds the seat history.

The record

Filing by filing, latest first

March 12, 202610-K filed
Richard Bartram signed the annual report of MBX Biosciences, Inc. on Form 10-K as Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer), filed March 12, 2026.
/s/ Richard Bartram Richard Bartram Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)
[1] Annual report on Form 10-K by MBX Biosciences, Inc., filed with the SEC on March 12, 2026. Read the filing. The record at CFO Tribune.

Sources

Annual report on Form 10-K, MBX Biosciences, Inc.. U.S. Securities and Exchange Commission, EDGAR, filed March 12, 2026. sec.gov; record.

Corrections and removal

If a line here is wrong, or Richard Bartram wants this profile taken down, write to corrections@cfospotlights.com. Corrections are made on the page with a dated note; removal requests are answered within 72 hours. The underlying filings stay public at the SEC.